Drawing for PRIMA BIOMED

USPTO serial 79191113

PRIMA BIOMED

Reviewed by CopyMark Law Group

Reg. 5262954Status 709
Filing date
Status date
Registration date
Aug 15, 2017
Examiner
LOBO, DEBORAH E
Law office
TMEG LAW OFFICE 109

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with PRIMA BIOMED?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Edward Playfair

Edward Playfair Adams and Reese LLP1600 West End AvenueSuite 1400Nashville, TN 37203

Goods and services

ClassDescriptionStatusFirst use
001Chemical reactants and reagents for scientific and laboratory use; chemicals for use in industry and science; antibodies and recombinant proteins for use in laboratories and for scientific purposesSECTION 71 - CANCELLED—
005Pharmaceutical and veterinary preparations for the treatment of cancer and autoimmune diseases [ ; ] *, * reactants and reagents for medical diagnostic purposes; diagnostic preparations and reagents for medical purposes; antibodies and recombinant proteins for use in medical applications, namely, adjuvants for the treatment of cancer and autoimmune diseases * ; none of the aforementioned being for use by lactating and pregnant women *SECTION 71 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Dec 21, 2024INNTTOTAL INVALIDATION PROCESSED BY THE IB—
Nov 30, 2024INTSTOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB—
Nov 29, 2024INPCINVALIDATION PROCESSED—
Nov 2, 2024INTRTOTAL INVALIDATION OF REG EXT PROTECTION CREATED—
Mar 1, 2024C71TCANCELLED SECTION 71—
Oct 12, 2022CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Oct 12, 2022TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Oct 12, 2022ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 12, 2022REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Oct 12, 2022COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Aug 15, 2022REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Aug 27, 2018INNAINVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE—
Aug 5, 2018INPRPARTIAL INVALIDATION OF REG EXT PROTECTION CREATED—
Feb 2, 2018ADCHCHANGE OF NAME/ADDRESS REC'D FROM IB—
Dec 22, 2017FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Dec 5, 2017FICSFINAL DISPOSITION NOTICE SENT TO IB—
Dec 5, 2017FIMPFINAL DISPOSITION PROCESSED—
Dec 5, 2017LIMELIMITATION FROM THE IB EXAMINED AND ENTERED—
Dec 5, 2017COC.CORRECTION UNDER SECTION 7 - PROCESSED—
Dec 5, 2017APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Nov 24, 2017LIMGLIMITATION OF GOODS RECEIVED FROM IB—
Nov 15, 2017FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Aug 30, 2017COC.CORRECTION UNDER SECTION 7 - PROCESSED—
Aug 23, 2017LIMELIMITATION FROM THE IB EXAMINED AND ENTERED—
Aug 17, 2017LIMGLIMITATION OF GOODS RECEIVED FROM IB—
Aug 15, 2017R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jul 28, 2017NREPNEW REPRESENTATIVE AT IB RECEIVED—
May 30, 2017NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
May 30, 2017PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
May 18, 2017NREPNEW REPRESENTATIVE AT IB RECEIVED—
May 10, 2017NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Apr 26, 2017PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Apr 19, 2017CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Apr 19, 2017TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Apr 19, 2017CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Apr 6, 2017PARITEAS VOLUNTARY AMENDMENT RECEIVED—
Apr 4, 2017DMCCDATA MODIFICATION COMPLETED—
Apr 4, 2017TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Apr 4, 2017CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Mar 30, 2017ALIEASSIGNED TO LIE—
Mar 16, 2017TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 16, 2017TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Feb 10, 2017NREPNEW REPRESENTATIVE AT IB RECEIVED—
Dec 16, 2016NREPNEW REPRESENTATIVE AT IB RECEIVED—
Oct 13, 2016RFNTREFUSAL PROCESSED BY IB—
Sep 16, 2016RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Sep 16, 2016RFRRREFUSAL PROCESSED BY MPU—
Sep 11, 2016RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Sep 10, 2016CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 7, 2016MAFRAPPLICATION FILING RECEIPT MAILED—
Sep 3, 2016DOCKASSIGNED TO EXAMINER—
Sep 3, 2016NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Sep 1, 2016REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance